COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03331393
Recruitment Status : Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : April 20, 2020
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Condition or disease Intervention/treatment
Rheumatoid Arthritis Other: Non-interventional

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis: A Chart Review Study
Actual Study Start Date : March 16, 2017
Estimated Primary Completion Date : May 14, 2020
Estimated Study Completion Date : May 14, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Abatacept

Group/Cohort Intervention/treatment
RA patients treated with Abatacept
Treated with Abatacept as a first-line biologic
Other: Non-interventional

RA patients treated with TNFi
Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
Other: Non-interventional

Primary Outcome Measures :
  1. number of patients discontinuing treatment before completing 12 months of therapy [ Time Frame: approximately 1 year ]
  2. time from treatment initiation to discontinuation [ Time Frame: approximately 1 year ]

Secondary Outcome Measures :
  1. Distribution of Healthcare Resource Utilization (HCRU) [ Time Frame: approximately 1 year ]
  2. Disease Activity Score [ Time Frame: approximately 1 year ]
    Disease Activity Score (DAS)

  3. Health Assessment Questionnaire [ Time Frame: approximately 1 year ]
    Health Assessment Questionnaire (HAQ)

  4. C-reactive Protein Levels [ Time Frame: approximately 1 year ]
    C-reactive protein (CRP) levels

  5. Erythrocyte Sedimentation Rate [ Time Frame: approximately 1 year ]
    Erythrocyte sedimentation rate (ESR) levels

  6. Joint Erosions [ Time Frame: approximately 1 year ]
    Measured by radiographic reports

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Rapidly-progressing RA patients initiating treatment with abatacept or TNFi at approximately 10 rheumatology practices across the US.

Inclusion Criteria:

  • 18 years of age at enrollment
  • Confirmed diagnosed with RA
  • Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site

Exclusion Criteria:

  • Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
  • Was followed at the site for less than 1 year since biologic treatment initiation
  • Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula

Other protocol defined inclusion/exclusion criteria could apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03331393

Layout table for location information
United States, California
Local Institution
Beverly Hills, California, United States, 90212
United States, Georgia
Local Institution
Gainesville, Georgia, United States, 30501
United States, Idaho
Local Institution
Coeur d'Alene, Idaho, United States, 83814-2644
United States, Minnesota
Local Institution
Eagan, Minnesota, United States, 55121
United States, South Carolina
Local Institution
Myrtle Beach, South Carolina, United States, 29572
United States, Washington
Local Institution
Richland, Washington, United States, 99352
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT03331393    
Other Study ID Numbers: IM101-686
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: April 20, 2020
Last Verified: April 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases